1. Home
  2. ZSQR vs SPRY Comparison

ZSQR vs SPRY Comparison

Compare ZSQR & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Z Squared Inc. Common Stock

ZSQR

Z Squared Inc. Common Stock

N/A

Current Price

$7.83

Market Cap

697.4M

Sector

Finance

ML Signal

N/A

Logo ARS Pharmaceuticals Inc.

SPRY

ARS Pharmaceuticals Inc.

HOLD

Current Price

$8.09

Market Cap

796.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZSQR
SPRY
Founded
N/A
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
697.4M
796.4M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
ZSQR
SPRY
Price
$7.83
$8.09
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$40.00
AVG Volume (30 Days)
992.3K
1.9M
Earning Date
N/A
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$84,278,000.00
Revenue This Year
N/A
$87.40
Revenue Next Year
N/A
$81.64
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.94
$6.66
52 Week High
$16.62
$18.63

Technical Indicators

Market Signals
Indicator
ZSQR
SPRY
Relative Strength Index (RSI) 21.61 42.07
Support Level N/A $7.41
Resistance Level N/A $8.61
Average True Range (ATR) 1.76 0.58
MACD -0.60 -0.16
Stochastic Oscillator 7.23 16.27

Price Performance

Historical Comparison
ZSQR
SPRY

About ZSQR Z Squared Inc. Common Stock

Z Squared Inc is a computing infrastructure company operating computing equipment and expanding into AI infrastructure. The Company's idea is to build on three principles: guide with power by acquiring operating sites where power is already flowing; build for AI workloads by converting that capacity into AI-ready colocation where the customer brings the compute and runs what it needs; and scale with discipline by deploying conversion capital site by site, against signed contracts and operational readiness.

About SPRY ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.

Share on Social Networks: